Neurocrine Biosciences, Inc. (1NBIX)
MTA
Closed
Oct 2, 2026
Day's Range
126.7052 wk Range
101.00Overview - 1NBIX - Neurocrine Biosciences, Inc.
Key Statistics
Valuation
Enterprise Value
10.82B
P/E (Trailing)
‪20.07‬
PEG Ratio
‪0.64‬
Price / Sales (TTM)
‪3.63‬
Price / Book
‪3.78‬
EV / EBITDA
‪13.50‬
Profitability
Gross Margin
‪97.58%‬
Profit Margin
‪20.91%‬
Operating Margin
‪22.19%‬
Return on Assets
‪11.70%‬
Return on Equity
‪22.08%‬
Ownership
Shares Outstanding
101.60M
Float
100.36M
Held by Insiders
‪1.06%‬
Held by Institutions
‪102.75%‬
Price stats
Beta
‪0.38‬
50-Day Avg
‪143.03‬
200-Day Avg
‪129.35‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 1NBIX - Neurocrine Biosciences, Inc.
Peers - 1NBIX - Neurocrine Biosciences, Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on MTA.
- 1NBIXMTANeurocrine Biosciences, Inc.12.55BMarket Cap+2.03%52-week change20.07P/E (Trailing)‪20.91%‬Profit Margin
- 1MRKMTAMerck KGaA55.65BMarket Cap+19.49%52-week change24.81P/E (Trailing)‪11.21%‬Profit Margin
- 1ZTSMTAZoetis Inc. Class A Common Stock48.46BMarket Cap-99.48%52-week change11.41P/E (Trailing)‪27.68%‬Profit Margin
- 1GALDMTAGalderma Group AG41.32BMarket Cap+15.70%52-week change53.11P/E (Trailing)‪14.57%‬Profit Margin
- 1VTRSMTAViatris Inc.12.51BMarket Cap+46.86%52-week change-5.09P/E (Trailing)‪-2.78%‬Profit Margin
- 1SOBIMTASwedish Orphan Biovitrum AB10.24BMarket Cap+36.40%52-week change117.09P/E (Trailing)‪4.51%‬Profit Margin
- 1LNTHMTALantheus Holdings Inc.3.88BMarket Cap+49.76%52-week change23.84P/E (Trailing)‪17.69%‬Profit Margin
Profile Summary - 1NBIX - Neurocrine Biosciences, Inc.
About
Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for movement disorders such as tardive dyskinesia and Huntington’s disease…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
